Patents Assigned to RIVER STONE BIOTECH, LLC
  • Patent number: 11781164
    Abstract: The invention relates to recombinant host cells that expresses one or more genes encoding a cytochrome P450 enzyme capable of N-demethylating and/O-demethylating reticuline and/or derivatives thereof, and also methods of producing a N-demethylated and/or O-demethylated reticuline and/or derivatives thereof, comprising cultivating the recombinant host of the invention in a culture medium under conditions in which the one or more genes encoding the cytochrome P450 enzymes is/are expressed. The reticuline and derivatives thereof are useful for providing access to naturally unavailable and chemically difficult-to-produce starting materials for opioids.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: October 10, 2023
    Assignee: RIVER STONE BIOTECH, LLC
    Inventors: Markus Schwab, Sumire Honda Malca, Philipp Friedrich Berninger, Jon Richard Heal, Joseph Michael Sheridan, Laura Tatjer Recorda, Rubini Maya Kannangara, Esben Halkjaer Hansen, Angela Manuela Ribeiro de Carvalho
  • Patent number: 11390628
    Abstract: Disclosed are methods for preparing buprenorphine from, for example, compounds such as nororipavine and northebaine.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: July 19, 2022
    Assignee: River Stone Biotech LLC
    Inventors: Patrick Roussel, Jimmy Van Wiltenburg, Marco Santella
  • Patent number: 11060071
    Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to have reduced levels or activity of one or more alcohol dehydrogenases or aldehyde reductases thereby increasing the production of benzylisoquinoline alkaloids and/or benzylisoquinoline alkaloid precursors.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: July 13, 2021
    Assignee: RIVER STONE BIOTECH, LLC
    Inventors: Esben Halkjaer Hansen, Markus Schwab, Philipp Berninger, Fanny Delgrange, Franziska Grassinger